These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 29357804)
61. Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker. Rago B; Tumey LN; Wei C; Barletta F; Clark T; Hansel S; Han X Bioconjug Chem; 2017 Feb; 28(2):620-626. PubMed ID: 28140559 [TBL] [Abstract][Full Text] [Related]
62. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates. Albers AE; Garofalo AW; Drake PM; Kudirka R; de Hart GW; Barfield RM; Baker J; Banas S; Rabuka D Eur J Med Chem; 2014 Dec; 88():3-9. PubMed ID: 25176286 [TBL] [Abstract][Full Text] [Related]
63. Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy. Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Sutton J; Bolton G; Zhou D; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A PLoS One; 2015; 10(7):e0132282. PubMed ID: 26161543 [TBL] [Abstract][Full Text] [Related]
64. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Oflazoglu E; Stone IJ; Gordon K; Wood CG; Repasky EA; Grewal IS; Law CL; Gerber HP Clin Cancer Res; 2008 Oct; 14(19):6171-80. PubMed ID: 18809969 [TBL] [Abstract][Full Text] [Related]
65. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas. Zhang L; Fang Y; Kopeček J; Yang J Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824 [TBL] [Abstract][Full Text] [Related]
66. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192 [TBL] [Abstract][Full Text] [Related]
67. Linker technologies for antibody-drug conjugates. Nolting B Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142 [TBL] [Abstract][Full Text] [Related]
68. An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates. Li Y; Gu C; Gruenhagen J; Yehl P; Chetwyn NP; Medley CD MAbs; 2016; 8(4):698-705. PubMed ID: 26891281 [TBL] [Abstract][Full Text] [Related]
69. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Agarwal P; Bertozzi CR Bioconjug Chem; 2015 Feb; 26(2):176-92. PubMed ID: 25494884 [TBL] [Abstract][Full Text] [Related]
70. An isotopically tagged azobenzene-based cleavable linker for quantitative proteomics. Qian Y; Martell J; Pace NJ; Ballard TE; Johnson DS; Weerapana E Chembiochem; 2013 Aug; 14(12):1410-4. PubMed ID: 23861326 [TBL] [Abstract][Full Text] [Related]
71. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224 [TBL] [Abstract][Full Text] [Related]
72. Research advances in peptide‒drug conjugates. Gong L; Zhao H; Liu Y; Wu H; Liu C; Chang S; Chen L; Jin M; Wang Q; Gao Z; Huang W Acta Pharm Sin B; 2023 Sep; 13(9):3659-3677. PubMed ID: 37719380 [TBL] [Abstract][Full Text] [Related]
73. Oxidation-labile linkers for controlled drug delivery. Carneiro A; Santana L; Matos MJ Bioorg Med Chem Lett; 2023 May; 87():129264. PubMed ID: 37004925 [TBL] [Abstract][Full Text] [Related]
75. Emerging Applications of Fluorogenic and Non-fluorogenic Bifunctional Linkers. Liu G; Hu J; Liu S Chemistry; 2018 Nov; 24(62):16484-16505. PubMed ID: 29893499 [TBL] [Abstract][Full Text] [Related]
76. Hypersensitive azobenzenes: facile synthesis of clickable and cleavable azo linkers with tunable and high reducibility. Eom T; Khan A Org Biomol Chem; 2020 Jan; 18(3):420-424. PubMed ID: 31904038 [TBL] [Abstract][Full Text] [Related]
77. PDCdb: the biological activity and pharmaceutical information of peptide-drug conjugate (PDC). Sun X; Li H; Chen Z; Zhang Y; Wei Z; Xu H; Liao Y; Jiang W; Ge Y; Zheng L; Li T; Wu Y; Luo M; Fang L; Dong X; Xiao M; Han L; Jia Q; Zhu F Nucleic Acids Res; 2024 Oct; ():. PubMed ID: 39360619 [TBL] [Abstract][Full Text] [Related]
78. Meeting report: 1st workshop of the peptide ADME discussion group. Sonesson A; Brady K; Bjørnsdottir I; Christensen JK Xenobiotica; 2021 Jan; 51(1):122-125. PubMed ID: 32048540 [TBL] [Abstract][Full Text] [Related]
79. Tunable pH-Sensitive 2-Carboxybenzyl Phosphoramidate Cleavable Linkers. Backer BS; Choy CJ; Davis AL; Browne ZS; Berkman CE Tetrahedron Lett; 2020 Mar; 61(12):. PubMed ID: 32205898 [TBL] [Abstract][Full Text] [Related]
80. Recent advances in construction of small molecule-based fluorophore-drug conjugates. Lang W; Yuan C; Zhu L; Du S; Qian L; Ge J; Yao SQ J Pharm Anal; 2020 Oct; 10(5):434-443. PubMed ID: 33133727 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]